The publicly funded NHS GGC is one of the largest scale users of Orion Health technology with over 25,000 users. Located in west central Scotland, it delivers services through 35 hospitals, 10 specialised units, and 50 healthcare centres and clinics.
Orion Health has expanded its offering within the NHS GGC to deliver two new modules, Medicines Reconciliation and Problem List. In addition, the NHS GGC is extending its use of Orion Health's Coordinate solution by adopting Healthcare Pathways to support care coordination and patient transfer and handover.
Jonathan Selby, Orion Health Executive Vice President for Europe, Middle East and Africa, says the new solution will provide healthcare professionals with a comprehensive picture of an individual's care needs and help reduce the potential for any medication related errors.
"It will allow authorised users to understand a full list of patient allergies and problems, and enable them to keep track of medication changes that occur during an inpatient episode of care. After the patient is discharged from hospital it will provide a summary of these changes to other care professionals," Mr Selby says.
Colin Henderson, Orion Health Managing Director for the UK and Ireland adds "NHS GGC has acted as a beacon site for others and has driven forward the integrated health information agenda in Scotland, as well as acting as a reference study for health regions across the UK and internationally."
"We are delighted to be increasing our offering to NHS GGC, and look forward to continuing to work with the Board on enabling better healthcare delivery."
Related news articles:
- Orion Health's Profile
About Orion Health
Orion Health (NZX:OHE) is a technology company that provides solutions which enable healthcare to over 90 million patients in more than 25 countries. Its open technology platform seamlessly integrates all forms of relevant data to enable population and personalised healthcare around the world. The company employs over 1200 people globally and is committed to continual innovation, investing over 30% of total operating revenue year to date in research and development, to cement its position at the forefront of Precision Medicine.